Sanofi and GSK Agree to Support COVAX with 200 Million COVID-19 Vaccines Doses

October 28, 2020
Pharmaceutical Technology Editors

The companies have signed a Statement of Intent with Gavi to make 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine available for distribution.

Sanofi and GSK announced on Oct. 28, 2020 that they have signed a Statement of Intent with Gavi, the legal administrator of the COVAX Facility, a global risk-sharing mechanism for the distribution of future COVID-19 vaccines, for the availability of 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine pending regulatory approval.

“To address a global health crisis of this magnitude, it takes unique partnerships. The commitment we are announcing today for the COVAX Facility can help us together stand a better chance of bringing the pandemic under control,” said Thomas Triomphe, executive vice-president and Global Head of Sanofi Pasteur, in an Oct. 28, 2020 press release. “This moment also reflects our long-term commitment to global health and ensures our COVID-19 vaccines are affordable and accessible to those most at risk, everywhere in the world.”

"Since we started working on the development of COVID-19 vaccines, GSK has pledged to make them available to people around the world,” added Roger Connor, president of GSK Vaccines, in the press release. “We are proud to be working with Sanofi to make this adjuvanted recombinant protein-based vaccine available to the countries signed up to the COVAX Facility as soon as possible—this has the potential to be a significant contribution to the global fight against COVID-19.”

Source: Sanofi